Search results
Showing 616 to 630 of 2105 results for technology appraisal
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic kidney disease in adults.
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 17 September 2026
Awaiting development Reference number: GID-TA11092 Expected publication date: TBC
In development Reference number: GID-TA10905 Expected publication date: TBC
Psychosis and schizophrenia in children and young people: recognition and management (CG155)
This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.
Nivolumab for previously treated advanced renal cell carcinoma (TA417)
Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.
Evidence-based recommendations on ixekizumab (Taltz) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]
Awaiting development Reference number: GID-TA11855 Expected publication date: TBC
Awaiting development Reference number: GID-TA11308 Expected publication date: TBC
Awaiting development Reference number: GID-TA11273 Expected publication date: TBC
Details and meeting dates of the antimicrobial evaluation panel
Details and meeting dates of the antimicrobial evaluation panel
Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.